Protagenic Therapeutics, Inc.
PTIX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | -$0 |
| % Growth | – | – | 100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | 200% |
| R&D Expenses | $0 | $0 | $1 | $1 |
| G&A Expenses | $0 | $1 | $1 | $1 |
| SG&A Expenses | $0 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $1 | -$0 | -$0 |
| Operating Expenses | $1 | $2 | $1 | $2 |
| Operating Income | -$1 | -$2 | -$1 | -$2 |
| % Margin | – | – | – | 6,534.6% |
| Other Income/Exp. Net | $0 | -$3 | $0 | $0 |
| Pre-Tax Income | -$1 | -$5 | -$1 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$5 | -$1 | -$2 |
| % Margin | – | – | – | 6,180.6% |
| EPS | -0.47 | -1.37 | -2.75 | -0.24 |
| % Growth | 65.7% | 50.2% | -1,045.8% | – |
| EPS Diluted | -0.47 | -1.37 | -2.75 | -0.24 |
| Weighted Avg Shares Out | 2 | 4 | 1 | 7 |
| Weighted Avg Shares Out Dil | 2 | 4 | 1 | 7 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$5 | -$1 | -$2 |
| % Margin | – | – | – | 6,128.9% |